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Introduction
By April 1, 2020, over 810,000 confirmed cases and 40,000 confirmed deaths were reported due 
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ABSTRACT
Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused 
devastation in over 200 countries. Italy, Spain, and the United States (US) were most severely 
affected by the first wave of the pandemic. The reasons why some countries were more 
strongly affected than others remain unknown. We identified the most-affected and less-
affected countries and states and explored environmental, host, and infrastructure risk factors 
that may explain differences in the SARS-CoV-2 mortality burden. 
Methods: We identified the top 10 countries/US states with the highest deaths per population 
until May 2020. For each of these 10 case countries/states, we identified 6 control countries/
states with a similar population size and at least 3 times fewer deaths per population. We 
extracted data for 30 risk factors from publicly available, trusted sources. We compared case 
and control countries/states using the non-parametric Wilcoxon rank-sum test, and conducted 
a secondary cluster analysis to explore the relationship between the number of cases per 
population and the number of deaths per population using a scalable EM (expectation–
maximization) clustering algorithm. 
Results: Statistically significant differences were found in 16 of 30 investigated risk factors, 
the most important of which were temperature, neonatal and under-5 mortality rates, the 
percentage of under-5 deaths due to acute respiratory infections (ARIs) and diarrhea, and 
tuberculosis incidence (p < 0.05) 
Conclusion: Countries with a higher burden of baseline pediatric mortality rates, higher 
pediatric mortality from preventable diseases like diarrhea and ARI, and higher tuberculosis 
incidence had lower rates of coronavirus disease 2019-associated mortality, supporting the 
hygiene hypothesis. 
Keywords: Coronavirus; Environment; Mortality; Public health  
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to severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) globally [1]. In the initial stages of the pandemic 
of coronavirus disease 2019 (COVID-19), which is caused 
by SARS-CoV-2, the incidence and mortality rates varied 
widely in different countries. Among  the countries with 
the highest incidence and mortality rates due to COVID-19, 
certain populous countries such as the United States 
(US), Brazil, and Mexico were particularly affected [1]. The 
trajectories of COVID-19-specific mortality rates highlight 
the discrepancies of the COVID-19 impact worldwide. 
Within the US, New York City became the epicenter of the 
US and was particularly hard-hit early. In the first month 
following the confirmation of COVID-19, 130,689 cases were 
identified and the mortality rate was 244 deaths per million. 
In comparison, Pennsylvania, which has a comparable total 
population size to New York City, had 28,685 confirmed 
cases in the first month and a significantly lower mortality 
rate, at 59 deaths per million [1]. Similar discrepancies were 
noted across different countries such as Italy and France, 
which have comparable population sizes; however, Italy 
had 69,176 confirmed cases and 126 deaths per million 
by the end of the first month, as reported by the World 
Health Organization (WHO) [1], whereas France had 43,977 
confirmed cases in the first month and a lower mortality 
rate, at 45 deaths per million, within the same period [1]. 
Based on variations at the state, regional, and national 
levels, as well as the beliefs of leaders, different policies and 
practices were implemented to contain the pandemic with 
varying success. The extent of the contribution of natural and 
environmental factors to variation in the COVID-19 incidence 
and mortality rates across different countries is unclear, 
as is the contribution of various policies implemented by 
countries and regions. Consequently, we estimated the 
mortality rates in the first month of the pandemic for all 
countries, as the total number of cases of COVID-19 is not yet 
known given gaps in testing for COVID-19 as reported by the 
WHO [1]. All countries were assessed in their first month of 
the pandemic, and factors associated with high morbidity 
and mortality were explored. This has implications because 
it can provide insights into what makes a society vulnerable 
to the rapid spread of COVID-19, with relevance for the future. 
In particular, identifying the risk factors that contributed to 
variation in mortality rates has important implications for 
the second and third waves of the pandemic. A careful case-
control analysis of contributors (including environmental, 
natural, and policy differences) to the severity of disease 
and mortality in COVID-19 was conducted to shed light on 
discrepancies in the first wave of the pandemic globally. 
Materials and Methods
Cases and controls were selected by matching countries 
with the highest COVID-19 mortality rates compared to 
those with the lowest. Matching was done based on the 
population size and WHO region (where possible). This 
study covered the period between March and May 2020 
to represent the first wave of the COVID-19 pandemic. We 
shortlisted all countries that had at least 100 cases by March 
31 (106 countries), as identified by Ritchie et al. [2]. We 
referred to the day when a country reported its 100th case 
as day X. For each country, we took the time of 1 month (30 
days) after the day of the first 100 cases (day X). We referred 
to this as day Y, whereby Y = X + 30 days. All further data 
were obtained for day Y of each country, as identified by 
Ritchie et al. [3]. All countries were arranged in descending 
order by the total deaths/population in those 30 days, and 
the top 10 countries were selected. For countries with an 
area greater than 5,000,000 km2, the unit of comparison 
was by state/province. These countries included Russia, 
Canada, the US, Brazil, and Australia. The top 10 countries in 
terms of COVID-19 deaths per population were selected for 
analysis as cases. To select controls, countries and US states 
were listed by decreasing order of population.
For each case, 6 controls were matched according to the 
closest population size. Controls were selected based on 3 
criteria: (1) the control countries were closest in population 
size to the case country, (2) 2 controls were from the same 
WHO region and 4 from different WHO regions, and (3) the 
COVID-19 death rates per population of the controls were at 
least 3 times lower than that of the case (Table 1, Figure 1).
Data Sources, Collection Process, and Tool 
Based on 3 different contributors (the environment, 
infrastructure, and host-related factors), potential risk 
factors that may determine the severity of COVID-19 burden 
in these 3 categories were shortlisted (Table 2). For each 
variable, reliable sources of publicly available information 
for all countries were utilized. Data were manually entered in 
Microsoft Excel and a tool was utilized to process the data. A 
complete list of sources is found in Table S1. 
After piloting the data, 2 control countries (Taiwan and 
Hong Kong) had many missing variables due to the non-
availability of data, and variables were treated as missing. 
For 23 out of 30 variables, comparable data were not found 
for states within the US (Table S1). Therefore, data available 
for the entire country were used instead. For infrastructure 
factors, data for public transportation were missing; 
given high intercity  variability, only the top metropolitan 
city in the country was considered. Population size was 
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used to ascertain the top metropolitan city, and the public 
transportation system of the selected cities was analyzed for 
further analysis.
Data Analysis 
Temperatures in March and April were found separately, 
using the arithmetic mean to obtain the average temperature 
of March and April. Public transportation was divided into 4 
categories: (1) none, (2) over-ground transport system only 
(buses/trams), (3) underground mass public transport only, 
and (4) over-ground and underground transport systems. 
Data analysis was carried out in Stata 15.1 (StataCorp., College 
Station, TX, USA), and Power BI (Microsoft Corp., Redmond, 
WA, USA) was used for the graphics. Due to the skewed 
distribution of variables, data were reported as median and 
interquartile range. The non-parametric Wilcoxon rank-
sum test was used to compare factors between the 2 groups. 
The cluster analysis was performed using a scalable EM 
clustering algorithm, which iteratively refines an initial 
cluster model to fit the data and determines the probability 
that a data point exists in a cluster. The algorithm ends the 
process when the probabilistic model fits the data. The 
function used to determine the fit was the log-likelihood of 
the data given the model.
Ethical Approval 
Ethical approval was not required, as all information was 
freely available in the public domain.
Results 
Geographically, all cases were in the northern hemisphere; 
5 were states within the US, whereas the other 5 were Figure 1. Algorithm used to select case and control 
countries/states. 
Table 1. List of case and control countries/states
Case country/state Same  WHO region controls
Different  
WHO region controls
New Jersey Tennessee Indiana Austria United Arab 
Emirates
Hong Kong Belarus
Connecticut Oklahoma Utah Kuwait Bosnia and 
Herzegovina
Moldova Armenia
New York Florida Texas Australia Niger Sri Lanka Taiwan
Michigan Washington Arizona Jordan Sweden Portugal Kyrgyzstan
Louisiana Alabama Kentucky Georgia Slovakia New Zealand Croatia
Spain Uzbekistan Poland Argentina Iraq Afghanistan Algeria
Belgium Czech Republic Greece Tunisia Cuba Dominican 
Republic
Rwanda
Italy Turkey Ukraine South Africa Colombia South Korea Kenya
Netherlands Romania Kazakhstan Ecuador Guatemala Cambodia Senegal
United Kingdom Germany Russia Thailand Egypt Philippines Vietnam
WHO, World Health Organization.
All the countries that had at least
100 cases by Mar 31 (n = 106)
100th case day = day X
Period Y = 30 days from day X
(Y = X + 30) 
Total period Y deaths for each country was taken
Period Y deaths per population was calculated
Top 10 countries with highest period Y deaths per
population were selected
Countries with <1,000 deaths were excluded and
the next country was selected from the list
For each of the 10 countries selected, 2 controls were
selected from the same World Health Organization (WHO) 
region and 4 controls from any other WHO region
The control country should have had 3 times less deaths 




■ Same region controls: 10 × 2 = 20




■ Total: 10 + 20 + 40 = 70
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countries in Europe (Figure 2). Controls were located across 6 
continents (Figure 2). The risk factors that were significantly 
different in cases versus control countries/states are given in 
Figures 3 and 4; of the 30 risk factors that were investigated, 
16 were found to be significant. Host-related factors were also 
observed to contribute to the difference in mortality rates 
(Figures 5, 6). A secondary analysis was conducted to compare 
the number of cases and the number of deaths in period Y, 
and the results are shown in Figure 7. Italy and Spain had a 
much higher proportion of deaths per reported cases than the 
US. There were limited data for the case countries/states on 
Table 2. Comparison of risk factors in case and control countries and states (significant factors only)  
Risk factor Control Case p
Environmental factor
 March temperature (°C) 12.3 (4.1−20.8) 5 (2.5−8.6) 0.035
 April temperature (°C) 15.3 (9.6−21.6) 8.1 (7.6−11.7) 0.013
 Average temperature (°C) 13.5 (6.8−20.6) 6.6 (5.5−10.2) 0.023
 UV light index (J/m²) 3,230 (2,138−4,862) 1,662 (1,645−2,444) 0.008
Host factor
 Life expectancy at birth (y) 75.2 (71.5−77.6) 81.4 (81.2−82.8) 0.040
 Under-5 mortality rate (/1,000 live births) 10 (6−22) 4 (3−4) 0.003
 Neonatal mortality rate (/1,000 live births) 6 (3−12) 2 (2−2) 0.008
 Tuberculosis incidence (/100,000 population) 26.5 (5.5−69.0) 4.6 (2.3−8.0) 0.004
 % of under-5 deaths due to diarrhea 1.7 (0.4−5.4) 0.3 (0.2−0.4) 0.016
 % of under-5 deaths due to acute respiratory infection 1.0 (5.3−15.1) 1.8 (1.4−2.4) 0.002
 Presence of national BCG program 42 (70) 0 < 0.001
Infrastructure factor
 Education index 0.69 (0.60−0.78) 0.81 (0.79−0.86) 0.012
 Population density (people/km2) 90 (57−136) 275 (205−378) 0.017
 Human Development Index 0.77 (0.70−0.84) 0.92 (0.89−0.92) 0.003
 % of GDP on healthcare 6.8 (5.3−8.2) 9.6 (8.9−10.1) 0.014
 Population of age ≥ 65 (% of total population) 12 (5−16) 18 (16−19) 0.001
Data are presented as medians (interquartile range) or n (%).
IQR, interquartile range; UV, ultraviolet; BCG, Bacillus Calmette-Guérin; GDP, gross domestic product.
Figure 2. Map showing case and control countries/states.
Figure 1. 
All the countries that had at least
100 cases by Mar 31 (n = 106)
100th case day = day X
Period Y = 30 days from day X
(Y = X + 30) 
Total period Y deaths for each country was taken
Period Y deaths per population was calculated
Top 10 countries with highest period Y deaths per
population were selected
Countries with <1,000 deaths were excluded and
the next country was selected from the list
For each of the 10 countries selected, 2 controls were
selected from the same WHO region and 4 controls
from any other WHO region
The control country should have had 3 times less deaths 
per population during their period Y
 ■ Cases: 10
 ■ Same region controls: 10 x 2 = 20
 ■ Different region controls: 10 x 4 = 40
 ■ Total: 10 + 20 + 40 = 70
Figure 2. 
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stunting, malaria incidence, and poverty. 
Environmental Factors 
The case countries/states recorded lower average temperatures 
in March and April (6.6°C) than the controls within that period 
(13.5°C, p =0.023) (Table 2). The ultraviolet (UV) light index 
was lower in the case countries/states (1,662.0 J/m2) than in 
the controls (3,229.5 J/m2, p = 0.008) (Table 2).
Host-Related Factors
Among the host-related factors, pediatric and neonatal 
mortality rates, causes of under-5 deaths, adult life expectancy, 
and others were significantly different among the cases and 
controls. The neonatal mortality rate was 2 per 1,000 live births in 
the cases versus 6 per 1,000 live births in the controls (p =0.008) 






 ◆ UV light penetrationa,b)
 ◆ Life expectancya,b)
 ◆ Pediatric mortalitya,b)
 ◆ Deaths due to diarrheaa,b)
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 ◆ Body mass indexb)
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 ◆ Educationa,b)
 ◆ Population densitya,b)
 ◆ Human Development Indexa,b)
 ◆ Health care expenditurea,b)
 ◆ Public transportation system
 ◆ Healthcare faciltiesb)








Average temperature of March and April
Figure 3. Three domains of risk factors studied. 
a)Statistically significant differences noted between cases and controls. b)Individual State data was not available; therefore, data was 
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Figure 6. Comparison of top causes of under-5 deaths in 
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(Table 2). The under-5 mortality rates were 4 and 10 per 1,000 
live births in the cases and controls, respectively (p =0.003) 
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deaths were due to diarrhea, versus 1.7% in the controls (p =0.016) 
(Table 2). Furthermore, 1.8% of all under-5 deaths in the case 
countries/states resulted from acute respiratory infections, 
versus 10.0% in the controls (p =0.002) (Table 2, Figure 6). 
In the cases, the tuberculosis incidence was found to be 4.6 per 
100,000 population, versus 26.5 in the controls (p =0.004) (Table 2). 
National Bacillus Calmette-Guérin (BCG) vaccination programs 
were not present in the cases, whereas 42 control countries/
states (70%) had these programs (p <0.001) (Table 2). 
Infrastructure 
The education index was 0.81 in the case countries/states 
and 0.69 in the controls (p = 0.012), whereas the Human 
Development Index was 0.92 versus 0.77 in the case and 
control countries/states, respectively (p = 0.003) (Table 2). 
The case countries/states spent 2.87% of gross domestic 
product more than the control countries on healthcare, and 
this was a significant difference (p = 0.014). The population 
density was 3 times higher in the case countries/states than 
in the controls (275 vs. 90 people/km2 of land area, p = 0.017) 
(Table 2).
Discussion
The analysis of our data showed many interesting results. 
The cases were all high-income countries in North America 
and Europe. There was a significant difference in living 
standards between the case and control countries, with 
the controls belonging to the low-income group (overall) 
with poorer healthcare and education and higher mortality 
from diarrhea and respiratory infections in childhood. Our 
findings suggest that countries with poorer economies and 
health systems did not experience worse outcomes in the 
early stage of the COVID-19 pandemic. 
The baseline mortality due to acute respiratory infections 
was more than 5 times higher in the controls than in the 
cases. Our findings suggest that young children, including 
infants, who have a higher susceptibility and burden of 
other respiratory infections, may have milder COVID-19 
due to the long-term boost of the innate immune response, 
known as trained immunity, as noted by Netea et al. [4]. The 
case countries all had lower incidence rates of tuberculosis, 
as well as no national BCG vaccination programs. An 
association of anti-tuberculosis antibodies with decreased 
severity of COVID-19 has been reported by Kovacic [5] 
and Miller et al. [6]. Countries with a long-standing BCG 
program had some degree of protection against COVID-19, 
corroborating the finding of Escobar et al. [7] that every 
10% increase in the BCG index was associated with a 10.4% 
reduction in COVID-19 mortality. Taken together, the higher 
burden of tuberculosis and pediatric mortality in the control 
countries can be explained by the “hygiene hypothesis,” 
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which relates to the decreasing incidence of infections in 
Western countries, as identified by Stiemsma et al. [8]. 
Welliver [9] noted that temperature and the UV light index 
were significant indicators, whereby colder temperatures 
seemed to favor a high burden of COVID-19, similar to 
the associations of temperature with influenza and other 
respiratory viruses. However, further studies are needed 
to confirm this finding. Population density seems to 
have been a vital factor that differentiated the cases and 
controls. The case countries/states had more than 3 times 
the number of people living per square kilometer of land. 
This is a logical result, since crowding leads to higher rates 
of transmission of droplet infections. In countries with 
lower population densities, Corburn et al. [10] pointed 
out that most of the population lives in rural settings with 
automatic distancing, whereas heavily urbanized areas 
pose difficulties in implementing social distancing due to 
the living environment.  
It is of note that several of our indicators, including obesity, 
stunting, and tobacco use, proved not to be statistically 
significant. We suspected that the case countries/states 
would primarily have cities with underground mass public 
transit available, but our findings were insignificant. 
Seventy percent (7 out of 10) of our case countries/states 
and 51.7% (31 out of 60) of our controls had underground 
mass public transit available, and this difference was not 
statistically significant. Tobacco use and obesity, which are 
risk factors for many diseases, were also not found to be 
significant between the case and control countries/states. 
Stunting, malaria incidence, and poverty index data were 
not available for many developed countries. As malaria and 
stunting are not major public health concerns in that part of 
the world, these parameters are not rigorously documented. 
Moreover, these countries have stronger economies and 
have not been assigned a poverty index number, so this 
variable was treated as missing data.
The Cases of Spain, Italy, and the United States
Our secondary analysis revealed that Italy and Spain had 
much higher proportions of deaths among COVID-19 
cases than that of the US (Figure 7). One explanation is 
that the testing threshold for Spain and Italy was much 
higher, increasing the likelihood of high-risk patients 
testing positive. However, Roser et al. [11] reported that the 
COVID-19 positivity rates of Spain, Italy, and the USA were 
3% to 5%, 5% to 10%, and 10% to 20%, respectively. Another 
explanation is that in Italy and Spain, a higher percentage 
of the population is over 65 years of age than in the US. 
A more detailed look at the individual country numbers 
indicated that 23% of the population of Italy is over 65 
years of age, whereas the corresponding percentages in 
Spain and the US are 19% and 16%, respectively. This factor 
may have contributed to the high level of mortality in Italy, 
but other factors are also likely to have played a role. The 
contribution of population demographics to increased 
COVID-19 mortality has been explored by Kontis et al. [12], 
who showed a correlation with the elderly population 
across different countries. Another possible explanation 
posited by Islam et al. [13] is that the COVID-19 virus strains 
present in Europe were deadlier than the North American 
strains. A genome-wide association study of severe 
COVID-19 patients conducted by Severe Covid-19 GWAS 
Group et al. [14] identified a gene cluster on chromosome 
3 as a risk locus for respiratory failure. The COVID-19 
Host Genetics Initiative [15] reported that nearly 50% of 
individuals in South Asia are carriers of this suspicous 
region, while Zeberg and Paabo [16] identified that 16% of 
people in Europe are carriers. Although the specific genes 
contributing to the severity of COVID-19 remain elusive, 
other contributors, including socioeconomic changes and 
preexisitng conditions, may have contributed to the high 
disparities in the death toll.
Strengths 
We systematically explored 30 variables related to the life 
sciences, including climate, population demographics, public 
health indices, and infrastructure. The study employed a 
holistic approach aiming to account for many risk factors. By 
using mortality per population as the principal measure of 
severity of the disease, 2 goals were achieved: first, the study 
eliminated patients with mild disease and therefore focused 
only on those who were a burden on the health system, and 
second, a fair comparison was made between countries 
with larger and smaller populations. The control countries 
were matched based on population size for all dependent 
variables. Lastly, all data were obtained from publicly 
available, verifiable sources.
Limitations 
The study aimed to identify the top 10 countries and states 
that were worst affected by COVID-19 in the early stage of the 
pandemic. Many countries/states had a limited number of 
laboratory polymerase chain reaction testing kits and were 
unable to test a sufficient number of suspected individuals. 
The case and control countries/states were identified based 
on the COVID-19 mortality data from only March and April 
2020; analyzing the spread of the virus in the following 
months may yield different results regarding the top 10 
countries/states. For 23 of the 30 variables, data were not 
available for individual states of the USA and combined 
https://doi.org/10.24171/j.phrp.2021.12.2.03
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data of the USA were used, leaving no differences across the 
states. Furthermore, population-level data (not individual 
data) were employed, which may have caused this study to 
be affected by the ecological fallacy, which is an important 
bias in studies involving population-level data collection.
Conclusion 
The death toll following the first wave of the COVID-19 
pandemic was affected by all 3 types of determinants 
(environmental, host-related, and infrastucture-related). 
We investigated various factors that potentially contributed 
to the global discrepancy in mortality rates. Countries 
implemented various control measures such as suspending 
public transport and promoting physical isolation. Even as 
the national emergency responses varied across countries, 
significant impacts of key environmental, host-related, and 
infrastructure-related determinants were identified. Our 
results shine light on the epidemiological contributors to 
variation in COVID-19 mortality. Our findings may guide future 
researchers to investigate these parameters concerning 
COVID-19 and help deduce factors related to COVID-19 
preparedness for the second and third waves of the 
pandemic. Actions to mitagate future global health threats 
require identifying deficiencies in the existing health systems, 
as well as improving coordination and implementation.
Supplementary Material 
Table S1. All indicators except public transportation.
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